Search the Newsreel

Kymera Therapeutics (KYMR) Q2 2026 Earnings Call Transcript

Kymera Therapeutics reported strong financial results for Q2 2026, with $65 million in collaboration revenue and a cash runway extending into 2029. The company highlighted significant progress in its clinical pipeline, including accelerated enrollment for its lead immunology program KT-621, with top-line data expected …

Kymera Therapeutics (NASDAQ:KYMR) Sees Unusually-High Trading Volume - Still a Buy?

Kymera Therapeutics (NASDAQ:KYMR) experienced unusually high trading volume, with shares surging 185% to 2.09 million, despite a slight stock dip. The company reported better-than-expected quarterly earnings and a significant 465.2% year-over-year revenue increase. However, insider selling of approximately 3.6 million shares worth $387.6 million …

Nurix Therapeutics' STAT6 Degrader Likely to Receive Increased Recognition, RBC Says

Nurix Therapeutics' (NRIX) STAT6 degrader NX-3911 is likely to receive increased recognition after advancing into clinical development under its collaboration with Sanofi (SNY), RBC Capital Markets said in a Monday research note.The investment firm said limited preclinical data Silver Upgrade to read this MT …

HC Wainwright Issues Negative Outlook for KYMR Earnings

California State Teachers Retirement System Increases Stake in Kymera Therapeutics, Inc. $KYMR

The California State Teachers Retirement System increased its stake in Kymera Therapeutics (NASDAQ:KYMR) by 23% in the first quarter, owning 56,282 shares valued at $4.7 million. Despite recent insider selling, analyst sentiment for Kymera Therapeutics remains positive, with a "Moderate Buy" consensus rating and …

Q3 EPS Forecast for Kymera Therapeutics Cut by Analyst

Brookline Capital Markets has reduced its Q3 2026 EPS forecast for Kymera Therapeutics to a loss of $1.31 per share, though it maintained a "Buy" rating. Despite the lowered forecast, Kymera reported a strong Q2, beating revenue and EPS expectations due to milestone payments …

KYMR Q2 Earnings and Revenues Top Estimates on Gilead, Sanofi Payments

Kymera Therapeutics, Inc. Stock 12‑Month Price Target Raised to $128.91, Implies 23% Upside

Kymera Therapeutics, Inc. (KYMR) has seen its average 12-month price target increased by analysts from $127.18 to $128.91, implying a potential 23% upside from its August 4th closing price. The consensus rating among 24 covering analysts remains "Buy," with 21 recommending Buy and 3 …

Kymera Therapeutics Releases Q2 2026 Financial Results

Kymera Therapeutics reported its Q2 2026 financial results, posting a narrower-than-expected loss of $0.62 per share, surpassing the consensus estimate. The company's revenue surged to $65.0M, reflecting strong growth driven by its protein degradation platform. This performance indicates substantial year-over-year improvement and accelerating momentum …

KYMERA THERAPEUTICS, INC. : CITIGROUP RAISES TARGET PRICE TO $135 FROM $120

Citigroup has increased its target price for KYMERA THERAPEUTICS, INC. (KYMR.O) to $135, up from the previous target of $120. This adjustment reflects Citigroup's updated outlook for the pharmaceutical company. The article, disseminated by Reuters, serves as a financial news update for investors.

Accelerated KT-621 Trial and Narrower Loss Might Change The Case For Investing In Kymera Therapeutics (KYMR)

Kymera Therapeutics, Inc. has reported past second-quarter 2026 results showing a reduced net loss of US$61.21 million and lower basic and diluted loss per share of US$0.62, while also completing Phase 2b enrollment for its KT-621 atopic dermatitis trial around six months ahead of …

Kymera’s KT-621 atopic dermatitis trial closes enrollment six months early

Kymera's KT-621 atopic dermatitis trial, BROADEN2, has completed enrollment six months ahead of schedule, accelerating its topline readout to year-end 2026 and Phase 3 initiation to mid-2027. This rapid enrollment highlights potential confidence in the oral STAT6 degrader in a competitive therapeutic area. The …

Kymera Therapeutics (KYMR) Stock Faces A Revenue Durability Reckoning

Kymera Therapeutics (KYMR) reported Q2 earnings with a significant increase in collaboration revenue but continued substantial net losses. The company's stock saw a muted response despite meeting several execution milestones for its protein degrader platform, including advancements in clinical trials. Investors are now focused …

Kymera Therapeutics, Inc. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:KYMR) 2026-08-05

Kymera Therapeutics (NASDAQ:KYMR) Releases Earnings Results, Beats Estimates By $0.09 EPS

Earnings call transcript: Kymera beats Q2 2026 estimates on revenue surge

Kymera Therapeutics reported stronger-than-expected Q2 2026 results, surpassing revenue forecasts by over 100% and narrowing its adjusted loss. The biotech company highlighted significant progress in its clinical pipeline, particularly with the accelerated enrollment for its KT-621 atopic dermatitis study and the advancement of KT-579 …

Kymera Therapeutics, Inc. (KYMR) Reports Q2 Loss, Tops Revenue Estimates

Kymera Therapeutics, Inc. (KYMR) came out with a quarterly loss of $0.62 per share versus the Zacks Consensus Estimate of a loss of $0.64. This compares to a loss of $0.95 per share a year ago. These figures are adjusted for non-recurring items. This …

Earnings Flash (KYMR) Kymera Therapeutics, Inc. Reports Q2 Collaboration Revenue $65.0M, vs. FactSet Est of $32.8M

Kymera Therapeutics, Inc. (KYMR) reported Q2 collaboration revenue of $65.0 million, significantly exceeding the FactSet estimate of $32.8 million. This positive earnings flash indicates strong performance in its collaboration agreements. The company's Q2 net loss also narrowed, further demonstrating improved financial results.

Milestones boost Kymera Therapeutics (NASDAQ: KYMR) Q2 2026 collaboration revenue

Will Kymera (KYMR) New CMO Hire Quietly Reframe Its Immunology Execution Story?

Kymera Therapeutics has appointed Terence Rooney, MD, as its new Chief Medical Officer, bringing extensive immunology drug development experience to the company. This hire could significantly impact the strategy for Kymera's oral immunology portfolio, particularly ahead of crucial Phase 2b readouts for KT 621. …

Kymera earnings up next: Can degrader platform justify rally?

Kymera Therapeutics is preparing to report its second-quarter results, with analysts anticipating a loss of $0.73 per share on $31.17 million in revenue. Investors are keenly watching updates on its lead drug candidate, KT-621, for atopic dermatitis, as well as progress on other pipeline …

Kymera Therapeutics, Inc. $KYMR Stock Holdings Trimmed by Dimensional Fund Advisors LP

First Trust Advisors LP Boosts Stock Position in Kymera Therapeutics, Inc. $KYMR

Kymera Therapeutics (KYMR) Could Be 23% Undervalued On Its New CMO Appointment

Kymera Therapeutics is in focus after appointing Terence Rooney, MD, as Chief Medical Officer, with the stock currently trading about 23% below the average analyst price target. The company's fair value is estimated at $127.52, driven by the potential of its immunology pipeline to …

Kymera Therapeutics Inc (KYMR) Financial Health: Profitability & Balance Sheet Analysis

Kymera Therapeutics Inc (KYMR) currently holds a financial score of 8.29, ranking 46 out of 385 in the Biotechnology & Medical Research industry, indicating stable financial health and high operating efficiency. The company reported a significant year-over-year revenue increase of 55.50% to $34.37M, with …

Kymera Therapeutics Inc (KYMR) Institutional Confidence

This article analyzes the institutional confidence in Kymera Therapeutics Inc (KYMR), which has a high institutional shareholding score of 10.00, ranking 1st in its industry. Institutional shareholding proportion increased by 8.46% quarter-over-quarter, with Baker Bros. Advisors LP and Fidelity Management & Research Company LLC …

Price-Driven Insight from (KYMR) for Rule-Based Strategy

This article provides a price-driven analysis of Kymera Therapeutics Inc. (NASDAQ: KYMR) for rule-based trading strategies. It highlights weak near and mid-term sentiment, despite a strong long-term outlook, with an exceptional risk-reward setup. The analysis includes AI-generated signals and institutional trading strategies across different …

Kymera Therapeutics (KYMR) Projected to Announce Quarterly Earnings on Wednesday

Deutsche Bank Initiates Kymera Therapeutics(KYMR.US) With Hold Rating, Announces Target Price $120

Deutsche Bank has initiated coverage on Kymera Therapeutics (KYMR.US) with a Hold rating. The firm has set a target price of $120 for the company's stock.

KYMR Initiates Coverage By Deutsche Bank -- Rating Set to Hold

Kymera Therapeutics (KYMR) has received a "Hold" rating from Deutsche Bank with a price target of $120.00. GuruFocus indicates the stock is significantly overvalued by 334.5% compared to its GF Value™ of $24.23, and its GF Score™ of 46/100 points to below-average performance, particularly …

Deutsche Bank initiates Kymera stock with Hold on valuation concerns

Deutsche Bank has initiated coverage on Kymera Therapeutics (NASDAQ: KYMR) with a Hold rating and a $120.00 price target, citing valuation concerns despite the company's leading position in targeted protein degradation. The bank believes the stock's current price already reflects its base case for …

Kymera Therapeutics to Report Second Quarter 2026 Financial Results on August 5, 2026

Kymera Therapeutics, a clinical-stage biopharmaceutical company, announced it will report its second quarter 2026 financial results on August 5, 2026. The company will host a video conference call and webcast at 8:30 a.m. ET on that day to discuss the results. Kymera Therapeutics is …

Kymera Sets Aug. 5 Webcast for Second-Quarter Results

Kymera Therapeutics (NASDAQ: KYMR) will report its second-quarter 2026 financial results on August 5, 2026. The company will host a video conference call and webcast at 8:30 a.m. ET on the same day. Investors can register for the live event or access a replay …